PriceTargets.com logo

Alto Neuroscience - ANRO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 414.14%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.89 As of 12/20/2024 05:32 PM ET
▲ +0.17 (4.57%)

This chart shows the closing price for ANRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alto Neuroscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANRO

Analyst Price Target is $20.00
▲ +414.14% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Alto Neuroscience in the last 3 months. The average price target is $20.00, with a high forecast of $43.00 and a low forecast of $4.00. The average price target represents a 414.14% upside from the last price of $3.89.

This chart shows the closing price for ANRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Alto Neuroscience. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024Stifel NicolausLower TargetBuy ➝ Buy$32.00 ➝ $10.00
10/23/2024RODMAN&RENSHAWDowngradeStrong-Buy ➝ Hold
10/23/2024WedbushDowngradeOutperform ➝ Neutral$29.00 ➝ $4.00
10/23/2024Robert W. BairdLower TargetOutperform ➝ Outperform$32.00 ➝ $10.00
10/23/2024Rodman & RenshawDowngradeBuy ➝ Neutral
9/10/2024William BlairReiterated RatingOutperform
9/10/2024WedbushReiterated RatingOutperform ➝ Outperform$29.00 ➝ $29.00
9/3/2024WedbushInitiated CoverageOutperform$29.00
6/21/2024Rodman & RenshawInitiated CoverageBuy$43.00
6/12/2024William BlairReiterated RatingOutperform
5/15/2024William BlairReiterated RatingOutperform
3/25/2024Stifel NicolausReiterated RatingBuy ➝ Buy$32.00
2/27/2024William BlairInitiated CoverageOutperform
2/27/2024TD CowenInitiated CoverageOutperform
2/27/2024Robert W. BairdInitiated CoverageOutperform$32.00
2/27/2024Jefferies Financial GroupInitiated CoverageBuy$33.00
2/27/2024Stifel NicolausInitiated CoverageBuy$32.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 8 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
Mentions as of
11/21/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Alto Neuroscience logo
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Read More

Today's Range

Now: $3.89
Low: $3.65
High: $3.93

50 Day Range

MA: $5.55
Low: $3.64
High: $14.52

52 Week Range

Now: $3.89
Low: $3.56
High: $24.00

Volume

461,654 shs

Average Volume

370,741 shs

Market Capitalization

$104.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Alto Neuroscience?

The following Wall Street sell-side analysts have issued reports on Alto Neuroscience in the last twelve months: Jefferies Financial Group Inc., Robert W. Baird, Rodman & Renshaw, RODMAN&RENSHAW, Stifel Nicolaus, TD Cowen, Wedbush, and William Blair.
View the latest analyst ratings for ANRO.

What is the current price target for Alto Neuroscience?

0 Wall Street analysts have set twelve-month price targets for Alto Neuroscience in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 414.1%. Rodman & Renshaw has the highest price target set, predicting ANRO will reach $43.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $4.00 for Alto Neuroscience in the next year.
View the latest price targets for ANRO.

What is the current consensus analyst rating for Alto Neuroscience?

Alto Neuroscience currently has 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ANRO.

What other companies compete with Alto Neuroscience?

Other companies that are similar to Alto Neuroscience include REGENXBIO, Alumis, Akebia Therapeutics, Cryoport and Procaps Group. Learn More about companies similar to Alto Neuroscience.

How do I contact Alto Neuroscience's investor relations team?

The company's listed phone number is (650) 200-0412 and its investor relations email address is [email protected]. The official website for Alto Neuroscience is www.altoneuroscience.com. Learn More about contacing Alto Neuroscience investor relations.